A	O
fission	B:C1520210
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
multidrug	O
resistant	O
HIV	O
-	I:C0917721
1	I:C0917721
proteases	I:C0917721
.	O

A	O
fission	O
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
multidrug	O
resistant	O
HIV	B:C0917721
-	I:C0917721
1	I:C0917721
proteases	I:C0917721
.	O

HIV	B:C0917721
-	I:C0917721
1	I:C0917721
protease	I:C0917721
(	O
protease	O
)	O
is	O
an	O
essential	O
enzyme	O
for	O
viral	O
production	I:C0042774
.	O

HIV	O
-	I:C0917721
1	I:C0917721
protease	I:C0917721
(	O
protease	B:C0917721
)	O
is	O
an	O
essential	O
enzyme	O
for	O
viral	O
production	I:C0042774
.	O

HIV	O
-	I:C0917721
1	I:C0917721
protease	I:C0917721
(	O
protease	O
)	O
is	O
an	O
essential	O
enzyme	B:C0014442
for	O
viral	O
production	I:C0042774
.	O

HIV	O
-	I:C0917721
1	I:C0917721
protease	I:C0917721
(	O
protease	O
)	O
is	O
an	O
essential	O
enzyme	O
for	O
viral	B:C0042774
production	I:C0042774
.	O

Thus	O
,	O
PR	B:C0162714
inhibitors	I:C0162714
(	O
PR	O
inhibitors	I:C0162714
)	O
are	O
the	O
most	O
effective	O
class	O
of	O
anti-HIV	O
drugs	I:C0376565
.	O

Thus	O
,	O
PR	O
inhibitors	I:C0162714
(	O
PR	B:C0162714
inhibitors	I:C0162714
)	O
are	O
the	O
most	O
effective	O
class	O
of	O
anti-HIV	O
drugs	I:C0376565
.	O

Thus	O
,	O
PR	O
inhibitors	I:C0162714
(	O
PR	O
inhibitors	I:C0162714
)	O
are	O
the	O
most	O
effective	O
class	O
of	O
anti-HIV	B:C0376565
drugs	I:C0376565
.	O

However	O
,	O
the	O
main	O
challenge	O
to	O
the	O
successful	O
use	O
of	O
PI	B:C0162714
drugs	O
in	O
patient	O
treatment	O
is	O
the	O
emergence	O
of	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
)	O
.	O

However	O
,	O
the	O
main	O
challenge	O
to	O
the	O
successful	O
use	O
of	O
PI	O
drugs	B:C0013227
in	O
patient	O
treatment	O
is	O
the	O
emergence	O
of	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
)	O
.	O

However	O
,	O
the	O
main	O
challenge	O
to	O
the	O
successful	O
use	O
of	O
PI	O
drugs	O
in	O
patient	O
treatment	B:C0087111
is	O
the	O
emergence	O
of	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
)	O
.	O

However	O
,	O
the	O
main	O
challenge	O
to	O
the	O
successful	O
use	O
of	O
PI	O
drugs	O
in	O
patient	O
treatment	O
is	O
the	O
emergence	O
of	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
(	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
)	O
.	O

However	O
,	O
the	O
main	O
challenge	O
to	O
the	O
successful	O
use	O
of	O
PI	O
drugs	O
in	O
patient	O
treatment	O
is	O
the	O
emergence	O
of	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
)	O
.	O

This	O
study	B:C2603343
aimed	O
to	O
develop	O
a	O
fission	O
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
rapid	O
testing	O
of	O
new	O
PR	O
inhibitors	I:C0162714
that	O
combat	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
fission	B:C1520210
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
rapid	O
testing	O
of	O
new	O
PR	O
inhibitors	I:C0162714
that	O
combat	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
fission	O
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
rapid	O
testing	O
of	O
new	O
PR	B:C0162714
inhibitors	I:C0162714
that	O
combat	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
fission	O
yeast	I:C1520210
cell	I:C1520210
-	I:C1520210
based	I:C1520210
system	I:C1520210
for	O
rapid	O
testing	O
of	O
new	O
PR	O
inhibitors	I:C0162714
that	O
combat	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
.	O

Three	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	O
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	O
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	B:C0917721
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	O
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	B:C0917721
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	O
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	B:C0917721
PR	I:C0917721
)	O
protease	O
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	B:C0917721
gene	O
mutations	I:C0596611
,	O
respectively	O
.	O

Three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
were	O
isolated	O
from	O
HIV	O
-	I:C0019693
infected	I:C0019693
patients	O
that	O
carried	O
seven	O
(	O
M7PR	O
)	O
,	O
ten	O
(	O
M10	O
PR	I:C0917721
)	O
and	O
eleven	O
(	O
M11	O
PR	I:C0917721
)	O
protease	O
gene	B:C0596611
mutations	I:C0596611
,	O
respectively	O
.	O

They	O
were	O
cloned	B:C0598888
and	O
expressed	O
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	O
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	B:C0017262
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	O
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	O
in	O
fission	B:C0178453
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	O
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	O
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	B:C0086860
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	O
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	O
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	B:C0917721
-	O
specific	O
proteolysis	O
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	O
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	B:C0597304
and	O
drug	O
resistance	I:C0013203
.	O

They	O
were	O
cloned	O
and	O
expressed	O
in	O
fission	O
yeast	I:C0178453
under	O
an	O
inducible	O
promoter	I:C0086860
to	O
allow	O
the	O
measurement	O
of	O
protease	O
-	O
specific	O
proteolysis	O
and	O
drug	B:C0013203
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	O
viral	O
substrates	O
(	O
MA	O
↓	O
CA	O
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	B:C0597304
HIV	O
viral	O
substrates	O
(	O
MA	O
↓	O
CA	O
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	B:C0019682
viral	O
substrates	O
(	O
MA	O
↓	O
CA	O
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	O
viral	O
substrates	O
(	O
MA	B:C0042738
↓	O
CA	O
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	O
viral	O
substrates	O
(	O
MA	O
↓	O
CA	B:C0042738
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	O
viral	O
substrates	O
(	O
MA	O
↓	O
CA	O
and	O
p6	B:C0917721
)	O
and	O
to	O
confer	O
drug	O
resistance	I:C0013203
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
abilities	O
to	O
proteolyze	O
HIV	O
viral	O
substrates	O
(	O
MA	O
↓	O
CA	O
and	O
p6	O
)	O
and	O
to	O
confer	O
drug	B:C0013203
resistance	I:C0013203
.	O

Production	O
of	O
these	O
proteins	B:C0917721
in	O
the	O
fission	O
yeast	I:C0178453
caused	O
cell	O
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	O
stress	I:C0242606
and	O
altered	O
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	O
death	I:C0007587
.	O

Production	O
of	O
these	O
proteins	O
in	O
the	O
fission	B:C0178453
yeast	I:C0178453
caused	O
cell	O
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	O
stress	I:C0242606
and	O
altered	O
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	O
death	I:C0007587
.	O

Production	O
of	O
these	O
proteins	O
in	O
the	O
fission	O
yeast	I:C0178453
caused	O
cell	B:C2244509
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	O
stress	I:C0242606
and	O
altered	O
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	O
death	I:C0007587
.	O

Production	O
of	O
these	O
proteins	O
in	O
the	O
fission	O
yeast	I:C0178453
caused	O
cell	O
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	B:C0242606
stress	I:C0242606
and	O
altered	O
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	O
death	I:C0007587
.	O

Production	O
of	O
these	O
proteins	O
in	O
the	O
fission	O
yeast	I:C0178453
caused	O
cell	O
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	O
stress	I:C0242606
and	O
altered	B:C4014650
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	O
death	I:C0007587
.	O

Production	O
of	O
these	O
proteins	O
in	O
the	O
fission	O
yeast	I:C0178453
caused	O
cell	O
growth	I:C2244509
inhibition	I:C2244509
,	O
oxidative	O
stress	I:C0242606
and	O
altered	O
mitochondrial	I:C4014650
morphologies	I:C4014650
that	O
led	O
to	O
cell	B:C0007587
death	I:C0007587
.	O

Five	O
investigational	O
PR	B:C0162714
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	O
drug	O
Darunavir	O
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	B:C1520210
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	O
drug	O
Darunavir	O
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	B:C0041714
-	O
approved	O
PI	O
drug	O
Darunavir	O
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	B:C0162714
drug	O
Darunavir	O
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	O
drug	B:C0013227
Darunavir	O
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	O
drug	O
Darunavir	B:C1435444
(	O
Darunavir	O
)	O
as	O
control	O
.	O

Five	O
investigational	O
PR	O
inhibitors	I:C0162714
were	O
used	O
to	O
test	O
the	O
utility	O
of	O
the	O
established	O
yeast	O
system	I:C1520210
with	O
an	O
FDA	O
-	O
approved	O
PI	O
drug	O
Darunavir	O
(	O
Darunavir	B:C1435444
)	O
as	O
control	O
.	O

All	O
six	O
compounds	B:C0162714
suppressed	O
the	O
wildtype	O
PR	I:C0917721
(	O
wildtype	O
PR	I:C0917721
)	O
and	O
the	O
M7	O
PR	I:C0917721
-	O
mediated	O
activities	O
.	O

All	O
six	O
compounds	O
suppressed	O
the	O
wildtype	B:C0917721
PR	I:C0917721
(	O
wildtype	O
PR	I:C0917721
)	O
and	O
the	O
M7	O
PR	I:C0917721
-	O
mediated	O
activities	O
.	O

All	O
six	O
compounds	O
suppressed	O
the	O
wildtype	O
PR	I:C0917721
(	O
wildtype	B:C0917721
PR	I:C0917721
)	O
and	O
the	O
M7	O
PR	I:C0917721
-	O
mediated	O
activities	O
.	O

All	O
six	O
compounds	O
suppressed	O
the	O
wildtype	O
PR	I:C0917721
(	O
wildtype	O
PR	I:C0917721
)	O
and	O
the	O
M7	B:C0917721
PR	I:C0917721
-	O
mediated	O
activities	O
.	O

However	O
,	O
none	O
of	O
them	O
were	O
able	O
to	O
suppress	O
the	O
M10	B:C0917721
PR	I:C0917721
or	O
the	O
M11PR	O
.	O

However	O
,	O
none	O
of	O
them	O
were	O
able	O
to	O
suppress	O
the	O
M10	O
PR	I:C0917721
or	O
the	O
M11PR	B:C0917721
.	O

The	O
three	O
clinically	O
isolated	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
viral	O
proteolytic	O
activities	I:C0597304
and	O
drug	O
resistance	I:C0013203
in	O
the	O
fission	O
yeast	I:C0178453
.	O

The	O
three	O
clinically	O
isolated	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
viral	B:C0042776
proteolytic	O
activities	I:C0597304
and	O
drug	O
resistance	I:C0013203
in	O
the	O
fission	O
yeast	I:C0178453
.	O

The	O
three	O
clinically	O
isolated	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
viral	O
proteolytic	B:C0597304
activities	I:C0597304
and	O
drug	O
resistance	I:C0013203
in	O
the	O
fission	O
yeast	I:C0178453
.	O

The	O
three	O
clinically	O
isolated	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
viral	O
proteolytic	O
activities	I:C0597304
and	O
drug	B:C0013203
resistance	I:C0013203
in	O
the	O
fission	O
yeast	I:C0178453
.	O

The	O
three	O
clinically	O
isolated	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
maintained	O
their	O
viral	O
proteolytic	O
activities	I:C0597304
and	O
drug	O
resistance	I:C0013203
in	O
the	O
fission	B:C0178453
yeast	I:C0178453
.	O

Furthermore	O
,	O
those	O
viral	B:C0917721
mdrPR	I:C0917721
activities	O
were	O
coupled	O
with	O
the	O
induction	O
of	O
growth	O
inhibition	I:C2244509
and	O
cell	O
death	I:C0007587
,	O
which	O
could	O
be	O
used	O
to	O
test	O
the	O
PI	O
activities	O
.	O

Furthermore	O
,	O
those	O
viral	O
mdrPR	I:C0917721
activities	B:C0597304
were	O
coupled	O
with	O
the	O
induction	O
of	O
growth	O
inhibition	I:C2244509
and	O
cell	O
death	I:C0007587
,	O
which	O
could	O
be	O
used	O
to	O
test	O
the	O
PI	O
activities	O
.	O

Furthermore	O
,	O
those	O
viral	O
mdrPR	I:C0917721
activities	O
were	O
coupled	O
with	O
the	O
induction	O
of	O
growth	B:C2244509
inhibition	I:C2244509
and	O
cell	O
death	I:C0007587
,	O
which	O
could	O
be	O
used	O
to	O
test	O
the	O
PI	O
activities	O
.	O

Furthermore	O
,	O
those	O
viral	O
mdrPR	I:C0917721
activities	O
were	O
coupled	O
with	O
the	O
induction	O
of	O
growth	O
inhibition	I:C2244509
and	O
cell	B:C0007587
death	I:C0007587
,	O
which	O
could	O
be	O
used	O
to	O
test	O
the	O
PI	O
activities	O
.	O

Furthermore	O
,	O
those	O
viral	O
mdrPR	I:C0917721
activities	O
were	O
coupled	O
with	O
the	O
induction	O
of	O
growth	O
inhibition	I:C2244509
and	O
cell	O
death	I:C0007587
,	O
which	O
could	O
be	O
used	O
to	O
test	O
the	O
PI	B:C0162714
activities	O
.	O

Indeed	O
,	O
the	O
five	O
investigational	O
PR	B:C0162714
inhibitors	I:C0162714
and	O
Darunavir	O
suppressed	O
the	O
wildtype	O
PR	I:C0917721
in	O
fission	O
yeast	I:C0178453
as	O
they	O
did	O
in	O
mammalian	O
cells	I:C1512977
.	O

Indeed	O
,	O
the	O
five	O
investigational	O
PR	O
inhibitors	I:C0162714
and	O
Darunavir	B:C1435444
suppressed	O
the	O
wildtype	O
PR	I:C0917721
in	O
fission	O
yeast	I:C0178453
as	O
they	O
did	O
in	O
mammalian	O
cells	I:C1512977
.	O

Indeed	O
,	O
the	O
five	O
investigational	O
PR	O
inhibitors	I:C0162714
and	O
Darunavir	O
suppressed	O
the	O
wildtype	B:C0917721
PR	I:C0917721
in	O
fission	O
yeast	I:C0178453
as	O
they	O
did	O
in	O
mammalian	O
cells	I:C1512977
.	O

Indeed	O
,	O
the	O
five	O
investigational	O
PR	O
inhibitors	I:C0162714
and	O
Darunavir	O
suppressed	O
the	O
wildtype	O
PR	I:C0917721
in	O
fission	B:C0178453
yeast	I:C0178453
as	O
they	O
did	O
in	O
mammalian	O
cells	I:C1512977
.	O

Indeed	O
,	O
the	O
five	O
investigational	O
PR	O
inhibitors	I:C0162714
and	O
Darunavir	O
suppressed	O
the	O
wildtype	O
PR	I:C0917721
in	O
fission	O
yeast	I:C0178453
as	O
they	O
did	O
in	O
mammalian	B:C1512977
cells	I:C1512977
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	O
PR	I:C0917721
and	O
M11PR	O
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	O
drugs	O
including	O
Darunavir	O
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	B:C0917721
PR	I:C0917721
and	O
M11PR	O
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	O
drugs	O
including	O
Darunavir	O
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	O
PR	I:C0917721
and	O
M11PR	B:C0917721
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	O
drugs	O
including	O
Darunavir	O
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	O
PR	I:C0917721
and	O
M11PR	O
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	B:C0162714
drugs	O
including	O
Darunavir	O
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	O
PR	I:C0917721
and	O
M11PR	O
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	O
drugs	B:C0013227
including	O
Darunavir	O
.	O

Significantly	O
,	O
two	O
of	O
the	O
high	O
level	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
(	O
M10	O
PR	I:C0917721
and	O
M11PR	O
)	O
were	O
resistant	O
to	O
all	O
of	O
the	O
existing	O
PI	O
drugs	O
including	O
Darunavir	B:C1435444
.	O

This	O
observation	O
underscores	O
the	O
importance	O
of	O
continued	O
searching	O
for	O
new	O
PR	B:C0162714
inhibitors	I:C0162714
against	O
multidrug	O
resistant	I:C0917721
PRs	I:C0917721
.	O

This	O
observation	O
underscores	O
the	O
importance	O
of	O
continued	O
searching	O
for	O
new	O
PR	O
inhibitors	I:C0162714
against	O
multidrug	B:C0917721
resistant	I:C0917721
PRs	I:C0917721
.	O

